Literature DB >> 25535964

Diagnostic methods for fast-track identification of endometrial cancer in women with postmenopausal bleeding and endometrial thickness greater than 5 mm.

Margit Dueholm1, Edvard Marinovskij, Estrid Stær Hansen, Charlotte Møller, Gitte Ørtoft.   

Abstract

OBJECTIVE: This study aims to evaluate the diagnostic efficiency of pattern recognition by transvaginal ultrasonography (TVS) and gel infusion sonography (GIS) for identifying endometrial pathology and to compare this setup with a standard setup of endometrial sampling (ES), hysteroscopy with pattern evaluation (HY(pattern)), or magnetic resonance imaging (MRI).
METHODS: This study used a prospective cohort of 174 women with postmenopausal bleeding and endometrial thickness of 5 mm or greater. Resectoscopic biopsy (hysteroscopy with biopsy) samples or hysterectomy served as reference standard. Malignant and benign endometrial patterns were evaluated with TVS, GIS and HY(pattern) were then added. The efficiency of each diagnostic strategy, including ES and MRI findings (n = 83), was compared and evaluated against the reference standard.
RESULTS: ES, TVS, GIS, and HY(pattern) had high diagnostic efficiency (area under the curve) for malignancy diagnosis (ES, 0.90; TVS, 0.88; GIS, 0.92; HY(pattern), 0.91). When insufficient samples were incorporated, ES was less efficient than the other techniques. ES was not more efficient in the subgroup of women without localized lesions than in the subgroup of women with localized lesions. MRI and HY(pattern) added limited efficiency, whereas hysteroscopy with biopsy was most efficient.
CONCLUSIONS: As a first-line technique, pattern recognition on TVS, GIS, and HY(pattern) correctly identifies 9 of 10 women with malignancy and is superior to pattern recognition on ES when insufficient samples are included. Endometrial pattern evaluated with TVS and GIS is a fast and efficient first-line diagnostic tool that outperforms ES in women with or without localized lesions. Malignant patterns on TVS/GIS should warrant fast-track evaluation, whereas women with benign patterns may be selected for office or operative hysteroscopy. A fast-track diagnostic setup based on pattern recognition is presented.

Entities:  

Mesh:

Year:  2015        PMID: 25535964     DOI: 10.1097/GME.0000000000000358

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  5 in total

1.  Clinicopathologic Characteristics and Causes of Postmenopausal Bleeding in Older Patients.

Authors:  Hyen Chul Jo; Jong Chul Baek; Ji Eun Park; Ji Kwon Park; In Ae Cho; Won Jun Choi; Joo Hyun Sung
Journal:  Ann Geriatr Med Res       Date:  2018-12-31

2.  Multiparametric transvaginal ultrasound in the diagnosis of endometrial cancer in post-menopausal bleeding: diagnostic performance of a transvaginal algorithm and reproducibility amongst less experienced observers.

Authors:  Shimaa Abdalla; Hisham Abou-Taleb; Dalia M Badary; Wageeh A Ali
Journal:  Br J Radiol       Date:  2021-02-02       Impact factor: 3.039

3.  Common Causes of Postmenopausal Bleeding in Korean Women: 10-Year Outcomes from a Single Medical Center.

Authors:  Min Kyoung Kim; Yeon Soo Jung; Seung Joo Chon; Bo Hyon Yun; Sihyun Cho; Young Sik Choi; Byung Seok Lee; Seok Kyo Seo
Journal:  J Korean Med Sci       Date:  2017-05       Impact factor: 2.153

4.  Endometrial Cancer Risk Prediction According to Indication of Diagnostic Hysteroscopy in Post-Menopausal Women.

Authors:  Carlo Saccardi; Amerigo Vitagliano; Matteo Marchetti; Alice Lo Turco; Sofia Tosatto; Michela Palumbo; Luciana Serena De Lorenzo; Salvatore Giovanni Vitale; Marco Scioscia; Marco Noventa
Journal:  Diagnostics (Basel)       Date:  2020-04-27

5.  A prospective comparison of the diagnostic accuracies of ultrasound and magnetic resonance imaging in preoperative staging of endometrial cancer.

Authors:  Michael Wong; Tejal Amin; Nikolaos Thanatsis; Joel Naftalin; Davor Jurkovic
Journal:  J Gynecol Oncol       Date:  2022-01-17       Impact factor: 4.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.